Monday miscellany

Have you booked yet for CLT's Annual Intellectual Property Law Round-Up conference for 2010, which will be upon us on 28 January 2010. The venue is somewhere or other in Central London and IPKat team member Jeremy will be in the chair. To be sure of your booking, or for further particulars of the star-studded programme, click here.

The 1709 Blog asks this morning whether thierry Ehrmann's Abode of Chaos, currently threatened with destruction by a French court, might be able to claim the benefit of copyright protection and, if so, what would be the scope of protection available to it. For further information click here.

The full text of the judgment isn't yet available on BAILII, but the decision of the Court of Appeal for England and Wales in Dr Reddy's Laboratories (UK) Ltd v Eli Lilly & Co Ltd [2009] EWCA Civ 1362 is noted in this morning's Lawtel subscription service. The Court dismissed Dr Reddy's appeal against the decision of Mr Justice Floyd (noted by the IPKat here) not to revoke Eli Lilly's patent for the anti-psychotic olanzapine. Further comment on this decision will appear in due course.

If you've been following the Copenhagen climate talks last week and have been a bit confused by all the name-calling and accusations, you may not have spotted that intellectual property rights have not been explicitly mentioned in the final text of the Copenhagen Accord. For further information see this piece by Tove Iren S. Gerhardsen for the ever-vigilant Intellectual Property Watch.

Sweet & Maxwell has been swift to get its 2010 periodicals out ahead of the Christmas break. The IPKat has already received his copies of the January 2010 European Trade Mark Reports (which leads with the Belgian Court of Appeal decision in eBay v Polo/Lauren on the use of trade marks as search engine terms and 'essential function' doctrine) and the European Intellectual Property Review (there's an interesting piece by Terese Foged on licensing schemes in an on-demand world).
Monday miscellany Monday miscellany Reviewed by Jeremy on Monday, December 21, 2009 Rating: 5

1 comment:

  1. full text of the olanzapine decision now available here:


All comments must be moderated by a member of the IPKat team before they appear on the blog. Comments will not be allowed if the contravene the IPKat policy that readers' comments should not be obscene or defamatory; they should not consist of ad hominem attacks on members of the blog team or other comment-posters and they should make a constructive contribution to the discussion of the post on which they purport to comment.

It is also the IPKat policy that comments should not be made completely anonymously, and users should use a consistent name or pseudonym (which should not itself be defamatory or obscene, or that of another real person), either in the "identity" field, or at the beginning of the comment. Current practice is to, however, allow a limited number of comments that contravene this policy, provided that the comment has a high degree of relevance and the comment chain does not become too difficult to follow.

Learn more here:

Powered by Blogger.